ROHTO Pharmaceutical Co., Ltd. and EXORPHIA Co., Ltd.
have entered into a capital and business alliance to develop production technology for extracellular vesicles (EVs)
– aiming to expand their business through strategic collaboration in the field of Regenerative medicine.
August 20, 2025
ROHTO Pharmaceutical Co., Ltd. (Head office: Osaka City, President and Representative Director: Hidetoshi Segi, hereinafter referred to as "Rohto Pharmaceutical") and EXORPHIA Inc. (Chiyoda-ku, Tokyo, Representative Director and CEO: Koji Kuchiishi, hereinafter referred to as "EXORPHIA") are pleased to announce that they have entered into a capital and business alliance.
Background and purpose of the business alliance
Rohto Pharmaceutical has formulated the "ROHTO Group Comprehensive Management Vision 2030: Connect for Well-being" and is continuing to take on various challenges toward the future of medicine and healthcare with the aim of realizing a well-being society. In its Regenerative medicine business, it is conducting research and development centered on mesenchymal stromal cells (MSCs).
Exophia is a drug discovery startup challenging itself to develop innovative medical solutions using extracellular vesicles (EVs), including exosomes. Since its founding in 2019, it has been working on product development in various disease areas.
Through this business alliance, both companies will strategically leverage their respective resources in the field of Regenerative medicine, an area in which they are focusing, with the aim of expanding their businesses and enhancing corporate value.
EVs play a crucial role in intercellular communication by transporting physiologically active substances such as proteins and nucleic acids between cells, and are expected to have applications in various diseases.
We have begun joint research and development with the aim of developing production technology for electric vehicles (EVs) by combining the manufacturing infrastructure and quality control systems that Rohto Pharmaceutical has cultivated in its Regenerative medicine business with Exophia's EV manufacturing and development technologies.
Future outlook
The impact of this matter on our consolidated financial results for the fiscal year ending March 2026 is expected to be minor, and we will promptly inform you of any further matters that need to be disclosed.
Company Profile
ROHTO Pharmaceutical Co., Ltd.
| location |
1-8-1 Tatsumi-Nishi, Ikuno-ku, Osaka City |
| Establishment |
1949 |
| representative |
President and Representative Director Hidetoshi Segi |
| Business details |
Over-the-counter (OTC) drugs, skincare products, functional foods, ophthalmic products, Regenerative medicine, and contract development and manufacturing (CDMO) services. |
| Homepage |
https://www.rohto.co.jp/ |
EXORPHIA Co., Ltd.
| location |
Otemachi Building 6F, 1-6-1 Otemachi, Chiyoda-ku, Tokyo |
| Establishment |
2019 |
| representative |
Representative Director and CEO: Koji Kuchiishi |
| Business details |
Development, manufacturing, and sales of pharmaceuticals and high-performance additives (such as reagents for in vitro fertilization) using EVs. |
| Homepage |
https://exorphia.com/ |